Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clonidine for Neurocognitive Sequelae in Pediatric Cancer Survivors
NCT00166686Phase 2Withdrawn
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial comparing Clonidine with Placebo (2 arms). Primary endpoint: Efficacy of clonidine in the treatment of neurocognitive sequelae at 18 weeks. Status: withdrawn.
02
Drugs
clonidine
Beyond the preview
Go deeper on NCT00166686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00166686.